ORIC Pharmaceuticals' Engagement in Upcoming Conferences
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) is set to participate in several key investor conferences this September, where the company will have the opportunity to share its groundbreaking work in oncology. This clinical-stage biopharmaceutical company is committed to overcoming resistance in cancer treatment, developing therapies that significantly improve patient outcomes.
Conferences Scheduled for September
The management of ORIC Pharmaceuticals will take part in various investor conferences aimed at advancing dialogue with current and prospective investors. The details of the conferences are as follows:
Citi's 2025 Biopharma Back to School Summit
On September 3, 2025, ORIC Pharmaceuticals will participate in a fireside chat at 4:00 p.m. ET, alongside one-on-one meetings to offer more personalized interactions with investors.
2025 Wells Fargo Healthcare Conference
Following the Citi summit, the team will engage at the Wells Fargo Healthcare Conference on September 4, 2025, at 2:15 p.m. ET, providing more insights into their transformative approaches.
Cantor Global Healthcare Conference 2025
The conference line-up continues with the Cantor Global Healthcare Conference on September 5, 2025. There, ORIC will engage in discussions starting at 8:35 a.m. ET.
Morgan Stanley 23rd Annual Global Healthcare Conference
On September 9, 2025, the management will also hold one-on-one meetings, allowing investors to delve deeper into the company’s strategies and future directions.
Baird 2025 Global Healthcare Conference
The final event in this series is the Baird 2025 Global Healthcare Conference on September 10, 2025, at 1:25 p.m. ET, where management will again participate in a fireside chat.
Webcast Access and Future Availability
Investors who wish to catch up on these key discussions can find live webcasts through the investor section of the company's website. Replays of the events will remain available for 90 days post-conference, making it easy for stakeholders to stay updated.
About ORIC Pharmaceuticals, Inc.
ORIC is a pioneering biopharmaceutical entity focused on transforming cancer therapy through innovative treatments. Its principal products include ORIC-944, which targets mechanisms responsible for prostate cancer, and enozertinib (ORIC-114), a brain-penetrant inhibitor aimed at various genetically defined cancers. This dedicated research aims not just to treat, but also to effectively combat therapeutic resistance that challenges current treatments.
Company Contact Information
For inquiries, please contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com
Frequently Asked Questions
What is the focus of ORIC Pharmaceuticals?
ORIC Pharmaceuticals focuses on developing innovative therapies that address mechanisms of resistance in cancer treatments.
When will ORIC Pharmaceuticals participate in investor conferences?
ORIC will participate in several investor conferences throughout September 2025.
How can I access the webcasts of the conference?
Live webcasts will be accessible through the investor section of ORIC's website, with replays available for 90 days.
What are the key product candidates of ORIC Pharmaceuticals?
The main product candidates include ORIC-944 and enozertinib (ORIC-114), which target mechanisms in various types of cancer.
How can I contact ORIC Pharmaceuticals for more information?
You can reach out via email to Dominic Piscitelli or the company’s general inquiries email for further information.
